Key facts
- DIOSynVax’s last known valuation is $31.6M (Dec 2025).
- It has raised $9.8M; the latest was Later Stage VC ($8.1M) in Dec 2025.
- Notable investors include Innovate UK, Gates Foundation, Parkwalk Advisors, Coalition for Epidemic Preparedness Innovations, Flu lab — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for DIOSynVax
- ·The full record, as it builds
Funding rounds
No funding rounds for DIOSynVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DIOSynVax
Operator of a vaccine antigen design company intended to accelerate vaccine development to maximize the protection against existing and future viruses. The company offers services that leverage technology to digitally design, immune-optimized selected and synthesized vaccines to achieve dramatic improvements in protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral hemorrhagic fevers, enabling doctors to treat and help patients recover quickly from diseases.
- Sector
- Healthcare
- HQ
- Hertford, United Kingdom
- Founded
- 2017
- Employees
- 17
- Website
- diosynvax.com/
- Ownership
- Privately Held (backing)
DIOSynVax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DIOSynVax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DIOSynVax in its N-PORT filings yet. We sweep new filings monthly.